Design Therapeutics, Inc. DSGN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -31.3%-8.7pp | -30.7%-11.6pp | -29.8%-12.1pp | -26.8%-8.7pp | -22.6%-2.4pp | |
| Return on assets | -29.8%-8.0pp | -29.2%-10.9pp | -28.5%-11.5pp | -25.8%-8.4pp | -21.8%-2.3pp | |
| Return on invested capital | -37.1%-7.3pp | -37.9%-12.0pp | -38%-12.9pp | -36.2%-10.4pp | -29.8%-3.0pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 22.3×-6.1× | 17.1×-12.2× | 18.7×-15.9× | 25.1×-16.3× | 28.4×-10.2× | |
| Quick ratio | 22.3×-6.1× | 17.1×-12.2× | 18.7×-15.9× | 25.1×-16.3× | 28.4×-10.2× | |
| Cash ratio | 1.3×-0.4× | 1.3×-1.4× | 1.4×-2.7× | 2.3×-4.9× | 1.7×-2.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $3.55-11.6% | $3.71-13.4% | $3.51-21.3% | $3.75-18.9% | $4.02-15.8% | |
| Valuation | ||||||
| Market capitalization | $860.66M+305% | $534.32M+52.9% | $428.82M+40.9% | $225.37M+19.1% | $219.1M-2.9% | |
| Enterprise value | $850.62M+324% | $519M+57.7% | $415.47M+50.3% | $207.61M+42.0% | $207.58M+4.3% | |
| Price / book | 3.9×+3.0× | 2.5×+1.1× | 2.1×+0.9× | 1.1×+0.3× | 1×+0.1× | |
| Free cash flow yield | -6.3%+16.2pp | -10.2%+2.2pp | -12.2%+3.0pp | -22.5%+4.7pp | -21.8%+2.2pp | |
| Earnings yield | -8.1%+18.4pp | -13.1%+1.1pp | -15.7%0.0pp | -28.2%-1.5pp | -25.6%+0.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Design Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Design Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.